Marshall Wace
EVLO

Marshall Wace’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Marshall Wace’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,940
Closed -$273K – 4440
2021
Q3 		$273K Sell
1,940
-1,190
-38% -$236K ﹤0.01% 2691
2021
Q2 		$861K Sell
3,130
-4,366
-58% -$1.1M ﹤0.01% 1890
2021
Q1 		$1.6M Buy
7,496
+5,427
+262% +$1.5M 0.01% 1430
2020
Q4 		$500K Buy
+2,069
New +$256K ﹤0.01% 1456
2019
Q4 		– Sell
-310
Closed -$38K – 2178
2019
Q3 		$38K Buy
+310
New +$42.6K ﹤0.01% 1530

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's EVLO Position: Q4 2021 in Review

Marshall Wace sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2021, closing a stake of 1,940 shares — an estimated $273K sold.

Marshall Wace first reported a position in EVLO in Q3 2019 and held it in 5 quarters. The position peaked at $1.6M in Q1 2021. 66 funds tracked by Wall St. Rank hold EVLO as of Q4 2021.

  • Marshall Wace reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 1,940 Evelo Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $273K.
  • Marshall Wace first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Marshall Wace's Evelo Biosciences, Inc. Common Stock position peaked at $1.6M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.